Enhancement of Auranofin-Induced Apoptosis in MCF-7 Human Breast Cells by Selenocystine, a Synergistic Inhibitor of Thioredoxin Reductase
Publication in refereed journal


Times Cited
Altmetrics Information
.

Other information
AbstractThioredoxin system plays an important role in regulation of intracellular redox balance and various signaling pathways. Thioredoxin reductase (TrxR) is overexpressed in many cancer cells and has been identified as a potential target of anticancer drugs. Auranofin (AF) is potent TrxR inhibitor with novel in vitro and in vivo anticancer activities. Selenocystine (SeC) is a nutritionally available selenoamino acid with selective anticancer effects through induction of apoptosis. In the present study, we demonstrated the synergistic effects and the underlying molecular mechanisms of SeC in combination with AF on MCF-7 human breast cancer cells. The results showed that SeC and AF synergistically inhibited the cancer cell growth through induction of ROS-dependent apoptosis with the involvement of mitochondrial dysfunction. DNA damage-mediated p53 phosphorylation and down-regulation of phosphorylated AKT and ERK also contributed to cell apoptosis. Moreover, we demonstrated the important role of TrxR activity in the synergistic action of SeC and AF. Taken together, our results suggest the strategy to use SeC and AF in combination could be a highly efficient way to achieve anticancer synergism by targeting TrxR.
All Author(s) ListChaoran Liu, Zhong Liu, Meng Li, Xiaoling Li, Yum-Shing Wong, Sai-Ming Ngai, Wenjie Zheng, Yibo Zhang, Tianfeng Chen
Journal namePLoS ONE
Year2013
Month1
Day14
Volume Number8
Issue Number1
PublisherPublic Library of Science
Article numbere53945
ISSN1932-6203
LanguagesEnglish-United Kingdom

Last updated on 2020-13-09 at 00:56